Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_001354304.2:c.209C>T

CA16020747

Gene: PAH (HGNC:5053)

Condition: phenylketonuria (MONDO:0009861)

Inheritance Mode: Autosomal recessive inheritance

UUID: 2f26a145-c76e-4696-9509-47d4ce44f81a

Approved on: 2020-07-24

Published on: 2020-07-24

HGVS expressions

NM_001354304.2:c.209C>T

NM_000277.1:c.209C>T

NM_000277.2:c.209C>T

NM_001354304.1:c.209C>T

NM_000277.3:c.209C>T

ENST00000307000.7:c.194C>T

ENST00000546844.1:c.209C>T

ENST00000548677.2:n.296C>T

ENST00000548928.1:n.131C>T

ENST00000549111.5:n.305C>T

ENST00000550978.6:n.193C>T

ENST00000551337.5:c.209C>T

ENST00000551988.5:n.298C>T

ENST00000553106.5:c.209C>T

ENST00000635500.1:n.177C>T

NC_000012.12:g.102894878G>A

CM000674.2:g.102894878G>A

NC_000012.11:g.103288656G>A

CM000674.1:g.103288656G>A

NC_000012.10:g.101812786G>A

NG_008690.1:g.27725C>T

NG_008690.2:g.68533C>T

Likely Pathogenic

PP4_Moderate PP3 PM2 PM3

Evidence Links 1

Expert Panel

Phenylketonuria VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Phenylketonuria VCEP

The c.209C>T (p.Ser70Phe) variant in PAH was reported in a Spanish patient with Mild HPA. A defect in the synthesis or regeneration in the pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels and by measuring the dihydropteridine reductase activity (PMID 27121329). This variant was detected in trans with pathogenic variant p.Ala300Ser. It is absent in population databases and was predicted deleterious using in silico data. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4 moderate, and PP3.

PP4_Moderate

Reported in a Spanish patient with Mild HPA-NT. A defect in the synthesis or regeneration in the pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels as well as by measuring the dihydropteridine reductase activity (PMID 27121329).

PP3

Predicted deleterious in SIFT, PolyPhen2, Mutation Taster, REVEL=0.832

PM2

Absent from 1000G, ESP, and gnomAD.

PM3

Detected in trans with pathogenic variant p.Ala300Ser. Segregation analysis was done (PMID 27121329).

PubMed:21307867

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.